ABIOMED (ABMD) : Next Century Growth Investors scooped up 2,766 additional shares in ABIOMED during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 611,291 shares of ABIOMED which is valued at $57.5 Million.ABIOMED makes up approximately 2.79% of Next Century Growth Investors’s portfolio.
Other Hedge Funds, Including , Marshall Wace Llp boosted its stake in ABMD in the latest quarter, The investment management firm added 1,285 additional shares and now holds a total of 13,319 shares of ABIOMED which is valued at $1.3 Million. ABIOMED makes up approx 0.01% of Marshall Wace Llp’s portfolio.First Trust Advisors Lp reduced its stake in ABMD by selling 12,595 shares or 39.67% in the most recent quarter. The Hedge Fund company now holds 19,152 shares of ABMD which is valued at $1.8 Million. ABIOMED makes up approx 0.01% of First Trust Advisors Lp’s portfolio. Financial Architects Inc added ABMD to its portfolio by purchasing 2,000 company shares during the most recent quarter which is valued at $188,160. ABIOMED makes up approx 0.07% of Financial Architects Inc’s portfolio.California Public Employees Retirement System reduced its stake in ABMD by selling 16,600 shares or 13.74% in the most recent quarter. The Hedge Fund company now holds 104,200 shares of ABMD which is valued at $9.9 Million. ABIOMED makes up approx 0.02% of California Public Employees Retirement System’s portfolio.Russell Frank Co reduced its stake in ABMD by selling 122,008 shares or 45.15% in the most recent quarter. The Hedge Fund company now holds 148,203 shares of ABMD which is valued at $14.4 Million. ABIOMED makes up approx 0.03% of Russell Frank Co’s portfolio.
ABIOMED closed down -0.68 points or -0.68% at $98.94 with 4,03,460 shares getting traded on Wednesday. Post opening the session at $99.81, the shares hit an intraday low of $98.8 and an intraday high of $99.95 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, ABIOMED reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.18. The company had revenue of $94.00 million for the quarter, compared to analysts expectations of $90.46 million. The company’s revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.24 EPS.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.